Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study

Vincent Chouraki, Alexa Beiser, Linda Younkin, Sarah Rosner Preis, Galit Weinstein, Oskar Hansson, Ingmar Skoog, Jean Charles Lambert, Rhoda Au, Lenore Launer, Philip A. Wolf, Steven Younkin, Sudha Seshadri

Research output: Contribution to journalArticlepeer-review


Background Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. Methods A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. Results Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71†0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76†0.98], P =.027) and AD (Aβ1-42: HR = 0.79 [0.69†0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72†0.96], P =.012). Conclusion Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.

Original languageEnglish
Pages (from-to)249-257.e1
JournalAlzheimer's and Dementia
Issue number3
StatePublished - 1 Mar 2015
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015 The Alzheimer's Association.


  • Alzheimer's disease
  • Aβ peptides
  • Epidemiology
  • Framingham
  • Heart
  • Incident
  • Incident dementia
  • Meta-analysis
  • Plasma biomarker
  • Study

ASJC Scopus subject areas

  • Clinical Neurology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Health Policy
  • Developmental Neuroscience
  • Epidemiology


Dive into the research topics of 'Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study'. Together they form a unique fingerprint.

Cite this